---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators. Topics: Fourth- and fifth-line alternatives: 2025 AHA/ACC guideline; Beta-blockers as secondary agents: 2025 AHA/ACC guideline; Alpha-1 blockers, central agents, and direct vasodilators: 2025 AHA/ACC guideline drug table; Order of alternative agents: 2024 ESC guideline; 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/beta-blockers-alpha-blockers-central-sympatholytics-and-direct-vasodilators"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Beta-blockers, Alpha-blockers, Central Sympatholytics, and Direct Vasodilators

<a id="topic-2.2.2.1.7-1"></a>

### Fourth- and fifth-line alternatives: 2025 AHA/ACC guideline

> “Other alternative fourth- and fifth-line drug therapies include BBs, alpha blockers, central sympatholytic drugs, and direct vasodilators.”
> “However, direct vasodilators such as hydralazine and minoxidil should be used in combination with a BB and a loop diuretic given their effects on sympathetic tone, sodium reabsorption, and fluid retention.”
> “The reduction in BP was greater than with addition of doxazosin or bisoprolol.”
> “The magnitude of reduction in 24-hour systolic and diastolic BP was greater with spironolactone than clonidine in a separate clinical trial.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-2"></a>

### Beta-blockers as secondary agents: 2025 AHA/ACC guideline

> “All other antihypertensive agents are considered secondary. BBs were less effective than first-line antihypertensive classes in preventing strokes and had a less favorable side effect profile; therefore, they should be reserved for adults with compelling indications.”
> “Beta blockers are not recommended as first-line agents unless the patient has CHD or HF.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-3"></a>

### Alpha-1 blockers, central agents, and direct vasodilators: 2025 AHA/ACC guideline drug table

> “These are associated with orthostatic hypotension, especially in older adults with a greater BP drop with first dose effect. These may be considered a second-line agent in patients with symptomatic benign prostatic hypertrophy.”
> “These are generally reserved as last-line choices because of significant CNS adverse effects, especially in older adults. Avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis.”
> “These are associated with sodium and water retention and reflex tachycardia and should be used with a diuretic and beta blocker. Hydralazine is associated with a drug-induced lupus-like syndrome at higher doses. Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.7-4"></a>

### Order of alternative agents: 2024 ESC guideline

> “An alternative to MRA as fourth-line treatment for BP lowering is the use of beta-blockers for persons who do not already have a compelling indication. A vasodilating beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a beta-blocker is chosen.”
> “Only thereafter should hydralazine, other potassium-sparing diuretics (amiloride and triamterene), centrally acting BP-lowering medications, or alpha-blockers be considered. Given multiple side-effects, minoxidil should only be considered if all other pharmacological agents prove ineffective in resistant hypertension.”
> “When not already prescribed for a compelling indication, beta-blockers should be considered in the treatment of resistant hypertension, though their BP-lowering effects appear to be less potent than spironolactone in the setting of resistant hypertension.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.7-5"></a>

### Alternatives when mineralocorticoid receptor antagonists are not tolerated: 2023 ESH guideline

> “When spironolactone and other MRAs are not tolerated or contraindicated (i.e. in CKD stage 4, eGFR <30 ml/min), bisoprolol (5– 10 mg/day), doxazosin extended release (4– 8 mg/day) or a centrally acting agent such as the alpha-adrenergic receptor agonists (clonidine, 0.1– 0.3 mg twice a day)”
> “However, bisoprolol and doxazosin reduced BP less effectively than spironolactone in the PATHWAY-2 trial”
> “Powerful vasodilators, such as hydralazine and minoxidil were occasionally used in the past, but they have been now virtually abandoned because of their association with serious side effects.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.7-6"></a>

### Spironolactone versus clonidine as the fourth drug: ReHOT trial

> “Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5-50 mg QD) or clonidine (0.1-0.3 mg BID).”
> “Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).”
> “However, spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.”

Source: [Krieger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29463627/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
